Dr. Baum was appointed President and Chief Executive Officer and Board Member of MethylGene in November 2012. Prior to joining MethylGene he was Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division. Dr. Baum was at Pfizer since 2003, serving in roles of increasing responsibility including as Vice President and Head of Oncology Development and as Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. He was responsible for the development of the oncology portfolio, including Axitinib (Inlyta®), Crizotinib (Xalkori®) and the approval of sunitinib (Sutent®) for the treatment of gastrointestinal stromal tumor (GIST) and renal cell carcinoma. Prior to joining Pfizer, Dr. Baum was responsible for the Phase I-IV development of several oncology compounds at Schering-Plough, including temozolomide (Temodar®) which was approved for the treatment of patients with advanced brain tumors. His career has included academic and hospital positions at Stanford and Emory universities, as well as positions of increasing responsibility within the pharmaceutical industry (Systemix, Searle, and Schering-Plough and Pfizer). Dr. Baum received his M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine in St. Louis, Missouri and completed his post-doctoral work and residency at Stanford University, California. Dr. Baum has received research support from the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts, and holds a number of patents and patent applications.

Mark J. Gergen was appointed to the position of Executive Vice President and Chief Operations Officer of MethylGene in February 2013. Mr. Gergen is a healthcare industry veteran and most recently was Senior Vice President, Corporate Development for Amylin Pharmaceuticals, Inc. At Amylin, Mr. Gergen was a member of the Executive Committee with broad responsibilities including corporate development, strategic planning, and alliance management. Prior to Amylin, Mr. Gergen held leadership roles in healthcare and life science companies. He was Executive Vice President of CardioNet, Inc. with broad responsibilities including those of CFO and COO. He served as Chief Financial and Development Officer and later CEO and Chief Restructuring Officer of Advanced Tissue Sciences, Inc. He also held key leadership and legal roles with Medtronic. Inc. Mr. Gergen began his career as an attorney and received his Juris Doctor degree from the University of Minnesota Law School and his undergraduate degree in business administration from Minot State University. Mr. Gergen has served on a number of private company and organization boards of directors.

Dr. Humphrey joined MethylGene in 2012 and leads the development of the Company’s clinical programs. Previously she was Vice President, Global Development Lead, Immuno-Oncology at Bristol-Myers Squibb (NYSE: BMY). During her eight-year tenure at Bristol-Myers Squibb, Dr. Humphrey supervised a number of in-licensed and internal development programs including the Phase II – IV development of ipilimumab (YERVOY®), which achieved global approval for the treatment of metastatic melanoma in 2011. From 1997 until 2003 Dr. Humphrey held increasingly senior clinical development positions at Bayer (XETRA: BAYN), leading the IND filing and the development of the multiple kinase inhibitor sorafenib (Nexavar®), which subsequently achieved global approval for advanced renal cell carcinoma and hepatocellular carcinoma. Dr. Humphrey received her B.A. degree in biochemistry from Harvard University, her M.D. degree from Case Western Reserve University, and completed her Medical Residency at the Johns Hopkins Hospital. From 1992 until 1997 Dr. Humphrey worked at the U.S. National Cancer Institute (NCI), first as a Clinical Oncology Fellow and later as a Staff Physician/Scientist in the NCI’s HIV and AIDS Malignancy Branch.